Conference Programme

Registration

Opening Remarks

Tony Jones, CEO, One Nucleus

Opening Keynote

What is Shaping Therapeutics Development in 2026: A Personal Perspective
Cathy Tralau-Stewart, Milner Therapeutics Institute

Scientific Breakthroughs Disrupting Bio Innovation

This session will focus on advances in molecular biology and bioengineering that are unlocking the next generation of therapeutics with a focus on the post-Covid momentum of mRNA therapeutics, and the delivery technologies enabling safer and more flexible approaches.

• 09:40 – 10:00 – 2 COMPANY CASE STUDIES
  • Company Case Study 1 – Rose Hughes, Cartesian Therapeutics
  • Company Case Study 2 – George Thom, AstraZeneca
• 10:00 – 10:40 – PANEL DISCUSSION
  Sponsored by
  
  • Moderator: Victoria English, Evernow Publishing Ltd
  • Panellists: Rose Hughes, Cartesian Therapeutics, George Thom, AstraZeneca, Jon Moore, Epitopea, Justin Wilson, Withers & Rogers

Morning Coffee and Networking Break

Disruptive Therapeutic Discovery Platform Technologies

The promise of data-centric and computational platforms in therapeutic discovery and development is widely recognised. Yet, as the number of tools and methodologies continues to grow, are we seeing genuine breakthroughs or simply an expanding technology landscape? Has the field reached a tipping point where these approaches have become truly transformative, or is that moment still ahead of us? 

• 11:10 – 11:30 – KEYNOTE PRESENTATION
  Nicole Mather, Wellcome Genome Campus

• 11:30 – 11:50 – 2 COMPANY CASE STUDIES
  • Company Case Study 1 – Edita Karosiene, Vugene
  • Company Case Study 2 – Alfred Lim, Etcembly

• 11:50 – 12:30 –  PANEL DISCUSSION
  • Moderator: Stephen Adams, Optimum Strategic Communications
  • Panellists: Nicole Mather, Wellcome Genome Campus, Edita Karosiene, Vugene, Alfred Lim, Etcembly

Lunch and Networking

Disruptive Regulatory and Clinical Pathways

This session will explore approaches that are challenging traditional regulatory and clinical processes, with the reduction of animal models serving as a key example.

• 13:30 – 13:50 – KEYNOTE PRESENTATION
  • Pelin Candarlioglu, 3D and 3Rs
• 13:50  – 14:10 – 2 COMPANY CASE STUDIES
  • Company Case Study 1 – Tomasz Kostrzewski, CN Bio
  • Company Case Study 2 – Hannah Amies, Luvida 
• 14:10  – 15:00 –  PANEL DISCUSSION
  • Moderator, Judit Molnar, One Nucleus Board member
  • Panellists: Leona Fitzgerald, PPD™ clinical research business of Thermo Fisher Scientific, Tomasz Kostrzewski, CN Bio, Hannah Amies, Luvida, Pelin Candarlioglu, 3D and 3Rs

Afternoon Coffee and Networking Break

Disruptive Business Models for Translational Research

Sponsored by

Exploring global operational models enabling biotech to scale more capital efficiently and competitively, the stakeholders involved, and growing importance of international regions like China.

• 15:30 – 16:10 – KEY LEARNINGS FROM THE BOSTON BOOTCAMP 2026
  • Moderator: Hazel Jones, Avellana Scientific
  • Panellists: Sheryl Caswell, Monument Therapeutics, Darcie Mulhearn, Stick Therapeutics, Darren Fergus, Profionics
• 16:10 – 16:30 – KEYNOTE PRESENTATION
  • Qaisar Rafiq, Kadans Science Partner
• 16:30 – 17:10 – PANEL DISCUSSION – FLEXING A GLOBAL INNOVATION ECOSYSTEM
  • Moderator: Mike Ward, Clarivate
  • Panellists: Claire Thompson, Agility Life Sciences, Julian Gough, OutSee, Qaisar Rafiq, Kadans Science Partner, Nina Marinsek, EY-Parthenon, Sophie Rose, WuXi AppTec

Closing Remarks

Prashant Shah, Chair, One Nucleus

Networking Drinks Reception

Sponsored by

End